Koichi Takahashi

1 month ago | nature.com | Courtney DiNardo |Wei-Ying Jen |Koichi Takahashi |Tapan M Kadia |Sanam Loghavi |Patrick K. Reville | +19 more

AbstractIntensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax.

Feb 7, 2024 | nature.com | Feiyang Ma |Natalia Baran |Jintan Liu |Ken Furudate |Paola Storti |Irene Ganan-Gomez | +10 more

AbstractDNA damage resistance is a major barrier to effective DNA-damaging therapy in multiple myeloma (MM). To discover mechanisms through which MM cells overcome DNA damage, we investigate how MM cells become resistant to antisense oligonucleotide (ASO) therapy targeting Interleukin enhancer binding factor 2 (ILF2), a DNA damage regulator that is overexpressed in 70% of MM patients whose disease has progressed after standard therapies have failed.

Jan 14, 2024 | nature.com | Koichi Takahashi |James Martin |Yu-Jung Tseng |Hidetaka Uryu

AbstractHematopoietic stem cells (HSCs) are capable of regenerating the blood system, but the instructive cues that direct HSCs to regenerate particular lineages lost to the injury remain elusive. Here, we show that iron is increasingly taken up by HSCs during anemia and induces erythroid gene expression and regeneration in a Tet2-dependent manner. Lineage tracing of HSCs reveals that HSCs respond to hemolytic anemia by increasing erythroid output.

Aug 5, 2023 | mdpi.com | Koichi Takahashi

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.